AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29231475
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation (TENS) at Neiguan (PC 6) and Zusanli (ST 36) for 4 weeks, 20 minutes twice a day.
Trial: 29231475
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medication and nursing (Control group).
Trial: 21355447
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (levofloxacin 500 mg)
Trial: 21355447
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (levofloxacin 500 mg)
Trial: 16472797
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d oral fluvastatin
Trial: 16472797
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d oral fluvastatin
Trial: 22803428
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy (Control)
Trial: 12901033
Drug: Pantoprazole suspension
RxNorm normalized name: pantoprazole Oral Suspension
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole suspension (20 mL of a suspension prepared from one crushed pantoprazole tablet and 840 mg of sodium bicarbonate solution)
Trial: 12901033
Drug: Pantoprazole tablet
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole tablet (one enteric-coated 40-mg pantoprazole tablet by mouth with 240 mL of water)
Trial: 7318439
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral contraceptive users (110 participants)
Trial: 31661976
Drug: AEO (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEO (0.25 g/kg feed)
Trial: 31661976
Drug: MOS (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOS (2 g/kg feed)
Trial: 31661976
Drug: PRO (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO (0.15 g/kg feed)
Trial: 31661976
Drug: DEO (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEO (0.25 g/kg feed)
Trial: 24837597
Drug: Cisplatin/5-fluorouracil 100/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/5-fluorouracil 100/1000 combined with panitumumab 9 mg/kg (Arm 1)
Trial: 17694802
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ketamine 0.3 mg/kg intravenously before the start of operation
Trial: 17694802
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ketamine 0.3 mg/kg intravenously at the end of operation
Trial: 11549529
Drug: Fluticasone propionate-salmeterol
RxNorm normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate-salmeterol combination therapy (FSC) administered twice daily (100 microg of fluticasone propionate and 50 microg of salmeterol)
Trial: 11549529
Drug: Fluticasone propionate-salmeterol
RxNorm normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate-salmeterol combination therapy (FSC) administered twice daily
Trial: 15526805
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg once daily)
Trial: 8880657
Drug: Behavioral marital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral marital therapy (BMT)
Trial: 9668941
Drug: Interactional couples
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactional couples therapy group
Trial: 9668941
Drug: No-marital-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-marital-treatment control group
Trial: 8062318
Drug: Extended-release ketoprofen
RxNorm normalized name: ketoprofen Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release ketoprofen 200 mg once daily for 3 weeks
Trial: 8062318
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg once daily for 3 weeks
Trial: 3546779
Drug: Oral diltiazem,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diltiazem, 180 mg/day
Trial: 3546779
Drug: Oral verapamil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil, 240 mg/day
Trial: 29484548
Drug: Active periodontal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active periodontal therapy (subgingival debridement); systemic antibiotics prescribed if Aggregatibacter actinomycetemcomitans was detected (10 AgP, 8 ChP); flap surgery if required.
Trial: 24787491
Drug: Automated Self-Administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Self-Administered 24-hour Recall (ASA24)
Trial: 24787491
Drug: Interviewer-administered Automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered Automated Multiple-Pass Method (AMPM)
Trial: 21095264
Drug: Intravenous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoetin α (up to 60,000 IU)
Trial: 15951327
Drug: i.v. tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. tramadol 1.5 mg kg(‐1) and i.v. ketorolac 0.3 mg kg(‐1)
Trial: 12460784
Drug: Ifosfamide 5
RxNorm normalized name: ifosfamide 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day), every 3 weeks
Trial: 12460784
Drug: Ifosfamide 3
RxNorm normalized name: ifosfamide 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days), every 3 weeks
Trial: 12460784
Drug: Ifosfamide 5
RxNorm normalized name: ifosfamide 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day), second-line treatment
Trial: 12460784
Drug: Ifosfamide 3
RxNorm normalized name: ifosfamide 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days), second-line treatment
Trial: 12460784
Drug: Ifosfamide 5
RxNorm normalized name: ifosfamide 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day)
Trial: 12460784
Drug: Ifosfamide 3
RxNorm normalized name: ifosfamide 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days)
Trial: 7489439
Drug: Paracetamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol plus ketorolac
Trial: 1952133
Drug: Demand-dose PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand-dose PCEA (3 mL every 10 min without restriction)
Trial: 1952133
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (CEI) (0.125% bupivacaine with fentanyl at 12 mL/h)
Trial: 1952133
Drug: Demand-dose PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand-dose PCEA
Trial: 7030837
Drug: Prednisolone, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, 40 mg given orally on alternate days
Trial: 27390150
Drug: ABT-494 3
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 3 mg twice daily
Trial: 27390150
Drug: ABT-494 6
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 6 mg twice daily
Trial: 27390150
Drug: ABT-494 12
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 12 mg twice daily
Trial: 27390150
Drug: ABT-494 18
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 18 mg twice daily
Trial: 27390150
Drug: ABT-494 24
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 24 mg once daily
Trial: 17941871
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day plus hypolipaemic diet
Trial: 15982813
Drug: Alfentanil (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (plasma concentration 70ng/ml)
Trial: 15982813
Drug: Morphine high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine high dose (plasma concentration 30ng/ml)
Trial: 15982813
Drug: Morphine low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine low dose (plasma concentration 15ng/ml)
Trial: 19949319
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs tested
Trial: 11263274
Drug: Xin Mai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xin Mai Tong Capsule
Trial: 6480127
Drug: Toluene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toluene (50 ppm) and MEK (100 ppm) in combination
Trial: 31783777
Drug: Brushing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing of the palate and immersion of the prosthesis in 0.15% triclosan solution
Trial: 31783777
Drug: Brushing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing of the palate and immersion of the prosthesis in 0.25% sodium hypochlorite solution
Trial: 27721534
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg once a day for 12 weeks
Trial: 22869566
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of liposomal amphotericin B/kg/day
Trial: 22869566
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of liposomal amphotericin B/kg at time zero, followed by 5 mg/kg at 48 and 120 h
Trial: 17208102
Drug: Palatal osseointegrated
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatal osseointegrated implants combined with pendulum springs
Trial: 1582124
Drug: Slow-releasing nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-releasing nicardipine (20 mg two times daily)
Trial: 2417476
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (surgery and/or irradiation alone) - includes randomized control (RC) and concomitantly-treated (CC) patients
Trial: 30756411
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3 mL/kg 20% albumin over 30 minutes
Trial: 29261824
Drug: Varenicline tartrate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline tartrate, 1 mg twice daily for 16 weeks
Trial: 26688003
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab (two 375-mg/m2 infusions)
Trial: 26688003
Drug: Full-dose rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Full-dose rituximab (two 1000-mg infusions)
Trial: 18194413
Drug: Prophylactic Antithrombin
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic Antithrombin Replacement in Kids with ALL treated with L‐Asparaginase (PARKAA) study
Trial: 12773303
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion for 60 min
Trial: 30122620
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin at 1.8 mg/kg with gemcitabine 1000 mg/m2
Trial: 27605258
Drug: Ilaprazole 10
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 10 mg once daily
Trial: 27605258
Drug: Ilaprazole 15
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 15 mg once daily
Trial: 22009525
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin (CIP IV) 300 mg b.i.d.
Trial: 22009525
Drug: Intravenous meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous meropenem (MEM IV) 500 mg b.i.d.
Trial: 22009525
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin (CIP IV) 300 mg b.i.d. in upper gastrointestinal surgery patients.
Trial: 22009525
Drug: Intravenous meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous meropenem (MEM IV) 500 mg b.i.d. in upper gastrointestinal surgery patients.
Trial: 18611150
Drug: Bacopa monnieri
RxNorm normalized name: BACOPA MONNIERI WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacopa monnieri extract 300 mg/day
Trial: 17318006
Drug: Pharmacotherapy (PHT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (PHT)
Trial: 15730064
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure (PE) alone or in combination with cognitive restructuring
Trial: 11726307
Drug: Potassium chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium chloride (KCl) containing chewing gum used up to 6 times daily for 10 min each occasion for 3 weeks
Trial: 11764019
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg methylphenidate (MPH)
Trial: 9234034
Drug: Expectancy regarding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectancy regarding medication
Trial: 7685719
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of hyperosmolar (50%) glucose solution
Trial: 30932134
Drug: 2RDA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2RDA (2 times the recommended daily allowance of protein intake, 2g/kg/d)
Trial: 30932134
Drug: RDA (current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDA (current recommended daily allowance of protein intake, 0.8g/kg/d)
Trial: 24772415
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 65 mg kg(‐1) infusion in 250 mL 5% dextrose at 3.5 mL/min (Group M)
Trial: 24772415
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 65 mg kg(‐1) infusion (Group M)
Trial: 18608623
Drug: Family Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Weight School therapy program in group meetings
Trial: 12468603
Drug: Cracker with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cracker with cream cheese
Trial: 12468603
Drug: Oral stimulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral stimulation by fat
Trial: 12468603
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil capsules
Trial: 10369171
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behaviour Therapy (CBT) during hospital rehabilitation
Trial: 7547095
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium (120 mg day‐1)
Trial: 7009093
Drug: Poly A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly A. Poly U I.V. 30 mg per week for 6 weeks
Trial: 19067673
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg daily for 8 weeks
Trial: 28692586
Drug: Extended-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release metformin
Trial: 22166651
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus metformin (0.5 g, tid)
Trial: 22166651
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus metformin (0.5 g, tid) and pioglitazone (15 mg, qd)
Trial: 11092645
Drug: HRT 2
RxNorm normalized name: EE/NETHDRONE (EQV-FEMHRT 2.5/0.5) TAB,28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT 2 (1 mg 17beta‐estradiol plus 0.025 mg gestodene for 12 days every third month)
Trial: 11092645
Drug: HRT 1
RxNorm normalized name: FEMHRT 1/5 TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT 1 (1 mg 17beta‐estradiol plus 0.025 mg gestodene for 12 days every month)
Trial: 27171844
Drug: Oxandrolone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.1 mg/kg twice/day for 12 months)
Trial: 15917280
Drug: Education on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education on oral anticoagulation, anticoagulation files, and patient information booklets; Group B received feedback every 2 months; Group C used CoaguChek device; Group D received Dawn AC computer assisted advice
Trial: 15917280
Drug: Education on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education on oral anticoagulation, anticoagulation files, and patient information booklets
Trial: 12546514
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 4 weeks
Trial: 12546514
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 8 weeks
Trial: 12546514
Drug: Oral mesalazine
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mesalazine alone at 1.2 g/day during maintenance period
Trial: 12546514
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 8 weeks (specifically for left-sided colitis)
Trial: 2690913
Drug: Intravenous adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adriamycin 50 mg, vincristine 1 mg, cyclophosphamide 250 mg, methotrexate 150 mg and fluorouracil 250 mg (AVCMF) every 21 days for eight cycles
Trial: 1155990
Drug: Tetrachlorethylene (T.C.E.)
RxNorm normalized name: trichloroethylene
DrugBank: Trichloroethylene (DB13323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrachlorethylene (T.C.E.) - single dose
Trial: 1155990
Drug: Bephenium hydroxynaphthoate
RxNorm normalized name: Bephenium hydroxynaphthoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bephenium hydroxynaphthoate - single dose
Trial: 1155990
Drug: Pyrantel pamoate
RxNorm normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrantel pamoate - single dose
Trial: 1155990
Drug: Bephenium hydroxynaphthoate
RxNorm normalized name: Bephenium hydroxynaphthoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bephenium hydroxynaphthoate - three daily doses
Trial: 1155990
Drug: Pyrantel pamoate
RxNorm normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrantel pamoate - three daily doses
Trial: 31901090
Drug: Cold analgesic
RxNorm normalized name: MENTHOL 1 g in 100 g TOPICAL GEL [Ice Cold Analgesic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold analgesic technique
Trial: 31901090
Drug: Vibration analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration analgesic technique
Trial: 31901090
Drug: No-treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment arm (Control)
Trial: 22764364
Drug: Naltrexone implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone implant
Trial: 30880163
Drug: Oral naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naltrexone placebo
Trial: 29283224
Drug: Autonomic regulation
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic regulation therapy (ART) using right cervical vagus nerve stimulation (VNS)
Trial: 20615781
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl and propofol (group B)
Trial: 11788429
Drug: Intravenous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous terbutaline